Prof. Sibylle Loibl
Medical Oncologist
- German Breast Group GmbH
Germany
Germany
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Programmes developed by Prof. Sibylle Loibl
Other
Oncology
The Role of DDR and PARP inhibition (PARPi) in Oncology – BluePrints
Experts
Dr Violeta Serra, Prof. Jonathan A. Ledermann, Prof. Eric Pujade-Lauraine, Prof. Simon Boulton, Dr Mark J. O'Connor, Prof. Charlie Gourley, Dr Judith Balmaña, Prof. Sibylle Loibl-
Downloadable
Resources -
MIN
-
Sep 2021
Downloadable 
MIN
Sep 2021 
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Experts
Dr Judith Balmaña, Dr Rebecca Dent, Prof. Simon Boulton, Prof. Sibylle Loibl, Prof. Eric Pujade-Lauraine, Prof. Charlie Gourley, Dr Violeta Serra, Prof. Jonathan A. Ledermann-
Downloadable
Resources -
10 MIN
-
Sep 2021